The fall of Cassava Sciences’s Alzheimer’s drug, simufilam

On November 25, Cassava Sciences ended a Phase 3 trial of its controversial Alzheimer’s drug, simufilam, following years of scrutiny.

Illustration: Anna Kim, Photos: Adobe Stock By Caroline Catherman December 11, 2024 • 4 min read TOPICS: Pharma / Clinical Trials & Evidence Generation / Clinical Trials An upcoming Alzheimer’s drug that garnered millions in federal funding has officially been put to bed. Biopharmaceutical company Cassava Sciences announced on November 25 that it had discontinued its Phase 3 clinical trial of drug simufilam. The randomized, double-blind trial found no statistically significant change in patient cognition or function—its co-primary endpoints—after 52 weeks when comparing a 403-person experiment

related reading

• It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardiantheguardian.com
• Nintil - The failure of monoclonal antibody therapy for Alzheimer's Disease, implications for the Amyloid Cascade Hypothesisnintil.com
• “Real world” eligibility for aducanumab: A Podcast with Tim Anderson and Marco Canevelligeripal.org
• Contrary Research on X: "The Virtual Cell Revolution" / Xx.com
• The Psychopharmacology Of The FTX Crashastralcodexten.substack.com
• Amaranth Foundation - Longevity and Neuroscienceamaranth.foundation
• The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsnature.com
• Alzheimer’s drug trial explores gut-brain linknature.com
• Blood test boosts Alzheimer's diagnosis accuracy to 94.5%, clinical study showsmedicalxpress.com
• What the Aging Field Needs - Celine Haliouacelinehh.com
• Science — Cajal Therapeuticscajalneuro.com
• Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com